EUCTR2017-003256-22-DE进行中（未招募）1 期
Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma - R-CHOEP-brut
niversitätsklinikum Münster0 个研究点目标入组 40 人开始时间: 2017年11月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study.
- •2. Age between 18-60 years
- •3. Risk score 2 or 3 according to aaIPI
- •4. Histology: Primary diagnosis of
- •- DLBCL (NOS) or
- •- High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements or
- •- High-grade B-cell lymphoma, NOS
- •5. Performance status: ECOG 0-3
- •6. Stage: all stages according Ann Arbor
- •7. ANC: > 1000 cells/microliter (independent of growth factor support)
- •8. Platelet count = 100.000/mm3 or = 50.000/mm3 if bone marrow involvement independent of transfusion support in either situation.
- •9. ALT and AST: < 3 x ULN
- •10. Total Bilirubin: < 1.5 x ULN
- •11. Serum Creatinine: < 2 x ULN or estimated GFR (GFR [Cockcroft-Gault]) = 40 ml/min
- •12. Women of childbearing potential and men who are sexually active must be practising a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For male subjects, these restrictions apply for 6 months after last dose of study drug. For female subjects, they apply for 12 months after last dose of study drug.
- •13. Women of childbearing potential must have negative serum or urine beta-human chorionic gonadotropin pregnancy test at screening. Women who are pregnant or breast-feeding are ineligible for this study.
- •14. Willing/ able to adhere to the prohibitions and restrictions specified in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Vaccinated with live, attenuated vaccines within 4 weeks of inclusion.
- •2. Major surgery within 4 weeks of inclusion.
- •3. Any prior lymphoma-directed therapy (except pre-phase treatment).
- •4. Known central nervous system involvement.
- •5. Diagnosed or treated for malignancy other than DLBCL, in particular any other (indolent) lymphoma.
- •6. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional classification.
- •7. Bone marrow involvement > 25%
- •8. History of stroke or intracranial hemorrhage within six months of inclusion.
- •9. Requires anticoagulation with warfarin or equivalent vitamin K antagonist.
- •10. Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring IV antibiotics.
- •11. Requires treatment with strong CYP3A inhibitors.
- •12. Use of preparations containing St. John’s Wort.
- •13. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- •14. Concurrent treatment with other investigational agent or X-ray therapy.
- •15. Previous chemo- or radiotherapy for any other malignancy, in particular indolent lymphoma.
- •16. Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator’s opinion, compromises the patient’s ability to understand the patient information, to give informed consent or to comply with the study protocol.
- •17. Participation in another interventional clinical trial during this trial. There may be exceptions at the discretion of the coordinating investigator.
研究者
相似试验
招募中
1 期
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerMedulloblastomaGlioblastomaEpendymomaPrimary Brain TumorNCT05106296Theodore S. Johnson37
已完成
2 期
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaDiffuse Large B Cell LymphomaNCT03399513University Hospital Muenster40
进行中（未招募）
2 期
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell LymphomaMantle Cell LymphomaNCT02427620M.D. Anderson Cancer Center131
Unknown
3 期
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersIndolent B-cell LymphomasChronic Hepatitis BLymphoma, Small LymphocyticMantle-Cell LymphomaWaldenstrom's MacroglobulinaemiaChronic Lymphocytic LeukemiaFollicular LymphomaNCT02991638The University of Hong Kong62
进行中（未招募）
1 期
Intermittent ibrutinib in chronic lymphocytic leukemiaChronic lymphocytic leukemiaCTIS2023-508638-32-00Karolinska University Hospital50